Embla reposted this
Co-founder & Co-CEO @ Embla | On a mission to eradicate reductive approaches to weight loss | Medical doctor | Writing about health & society
Our focus on the price of weight loss medication is blinding us. Instead, we should talk more about this. → Dosage and time. Since its launch, GLP-1 medication like Novo Nordisk’s Wegovy has been criticised for its relatively high price point. While the price of medication is an important topic (affordability leads to access), there’s too little focus on these two parameters that — in the case of weight loss medication — matter just as much. Turns out, you don’t need the full 2.4 mg standard dose or life-long treatment to see meaningful, lasting results. According to our real-world Embla study, there’s a way to get better outcomes out of less medication. This means the average user can save on medicine costs and experience fewer side effects. Additionally, this approach helps the global supply last longer. I discuss this, and more, in an opinion piece in Jyllands-Posten. Link in comments 👇 #wegovy #semaglutide #obesity #weightmanagement #weightloss
There's so many benefits to focusing on dosage and time spent on the medication. Glad it's finally getting some attention 🌟
Absolutely agree! ⭐️ It's also crucial to ensure the dosage isn't too high, as this can suppress hunger and appetite excessively. Remember, maintaining a healthy diet is essential for overall well-being and health 🍎
I agree! 🙌🏼 It’s super important that this focus and perspective is a part of the debate.
Co-founder & Co-CEO @ Embla | On a mission to eradicate reductive approaches to weight loss | Medical doctor | Writing about health & society
3mohttps://jyllands-posten.dk/debat/breve/ECE17209804/pris-spiller-hovedrollen-i-debat-om-vaegttabsmedicin-men-dosis-burde-tage-rampelyset/